[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100548312":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":19,"centralContacts":20,"locations":26,"responsibleParty":43,"collaborators":19,"id":47,"slug":48,"hasResults":49,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":19,"eligibilityCriteria":52,"healthyVolunteers":53,"sex":54,"minAge":55,"maxAge":19,"enrollmentInfo":56,"targetDuration":19,"studyType":59,"phases":60,"briefSummary":62,"conditions":63,"keywords":19,"overallStatus":29,"whyStopped":19,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":76},{"fullName":5,"class":6},"First Affiliated Hospital of Chongqing Medical University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"[68Ga]Ga-Sa-DABI-4","EXPERIMENTAL","Patients will receive a single administration of \\[68Ga\\]Ga-Sa-DABI-4.",[13],"Drug: [68Ga]Ga-Sa-DABI-4",[15],{"type":16,"name":9,"description":17,"armGroupLabels":18,"otherNames":19},"DRUG","Each subject receives a single intravenous injection of \\[68Ga\\]Ga-Sa-DABI-4.",[9],null,[21],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},"Xiaoyang Zhang, PhD","CONTACT","023-89011755","zhangxy@mail.bnu.edu.cn",[27],{"facility":28,"status":29,"city":30,"state":31,"zip":32,"country":33,"countryCode":34,"cosmosGeoPoint":35,"geoPoint":40,"contacts":41},"The First Affiliated Hospital of Chongqing Medical University","RECRUITING","Chongqing","Chongqing Municipality","400016","China","CN",{"type":36,"coordinates":37},"Point",[38,39],106.55771,29.56026,{"lat":39,"lon":38},[42],{"name":22,"role":23,"phone":24,"phoneExt":19,"email":25},{"type":44,"investigatorFullName":45,"investigatorTitle":46,"investigatorAffiliation":5,"oldNameTitle":19,"oldOrganization":19},"PRINCIPAL_INVESTIGATOR","Xiaoyang Zhang","Principal Investigator","100548312","early-phase-1-68gaga-sa-dabi-4-pet-imaging-of-stimulator-of-interferon-gene-expression-in-cancer-patients-100548312",false,"NCT06419361","[68Ga]Ga-Sa-DABI-4 PET Imaging of Stimulator of Interferon Gene Expression in Cancer Patients","Inclusion Criteria:\n\n1. At least 18 years of age.\n2. Signed informed consent.\n3. Patients with suspected or newly diagnosed or previously malignant disease.\n\nExclusion Criteria:\n\n1. Patients with non-malignant disease.\n2. Patients with pregnancy.\n3. The inability or unwillingness of the research participant, parent or legal representative to provide written informed consent.\n4. Known or expected hypersensitivity to \\[68Ga\\]Ga-Sa-DABI-4 or any of its components.\n5. Any serious medical condition or extenuating circumstance which the investigator feels may interfere with the procedures or evaluations of the study.",true,"ALL","18 Years",{"count":57,"type":58},30,"ESTIMATED","INTERVENTIONAL",[61],"EARLY_PHASE1","Stimulator of interferon gene (STING) protein plays a vital role in the immune surveillance of tumor microenvironment. Monitoring STING expression in tumors benefits the relevant STING therapy. This study will investigate the safety, biodistribution and potential usefulness of a novel 68Ga-labeled agonist (\\[68Ga\\]Ga-Sa-DABI-4) for noninvasive positron emission tomography (PET) imaging of STING expression in the tumor microenvironment.",[64,65,66],"Stimulator of Interferon Gene","Cancer","Positron Emission Tomography","2025-05-29",{"date":69,"type":70},"2025-06-04","ACTUAL",{"date":72,"type":70},"2024-05-30",{"date":74,"type":58},"2026-12-31",{"name":5,"class":6},1]